Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_3
3
60%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

recruiting5100%

Recent Activity

5 active trials
Showing 5 of 5
recruitingphase_3

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161
recruitingphase_3

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480
recruitingphase_3

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT06499285
recruitingphase_2

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT04419649
recruitingphase_2

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760

Clinical Trials (5)

Showing 5 of 5 trials
NCT07623161Phase 3

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Recruiting
NCT07422480Phase 3

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Recruiting
NCT06499285Phase 3

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Recruiting
NCT04419649Phase 2

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Recruiting
NCT05037760Phase 2

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5